Novartis Ag (NVS) Revenue Growth (1y) (2010 - 2024)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Revenue Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
55.54% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
9.91% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
12.43% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
4.87% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
5.76% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
4.39% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
10.70% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
2.57% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2024 |
-52.92% |
| Dec 31, 2023 |
8,653.94% |
| Jun 30, 2023 |
6.07% |
| Mar 31, 2023 |
26.07% |
| Dec 31, 2022 |
-99.40% |
| Sep 30, 2022 |
4.42% |
| Jun 30, 2022 |
-0.12% |
| Mar 31, 2022 |
-8.54% |
| Dec 31, 2021 |
17,268.60% |
| Sep 30, 2021 |
-5.04% |
| Jun 30, 2021 |
7.25% |
| Mar 31, 2021 |
17.57% |
| Jun 30, 2020 |
-25.90% |
| Mar 31, 2020 |
1.70% |
| Jun 30, 2019 |
13.18% |
| Mar 31, 2019 |
10.85% |
| Dec 31, 2018 |
12.87% |
| Sep 30, 2018 |
32.81% |
| Jun 30, 2018 |
14,349.74% |
| Dec 31, 2017 |
-99.58% |
| Sep 30, 2017 |
2.67% |
| Jun 30, 2017 |
21.38% |
| Dec 31, 2016 |
74,010.77% |
| Sep 30, 2016 |
128,965,517,241,279.33% |
| Mar 31, 2016 |
26.00% |
| Dec 31, 2015 |
74,712,543.68% |
| Sep 30, 2015 |
-100.00% |
| Mar 31, 2015 |
80.72% |
| Dec 31, 2010 |
-100.00% |
| Jun 30, 2010 |
11.09% |
| Mar 31, 2010 |
124,945,926,459,885.58% |
